Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) CEO Robert I. Blum sold 12,500 shares of the business’s stock in a transaction on Wednesday, March 15th. The shares were sold at an average price of $37.26, for a total transaction of $465,750.00. Following the transaction, the chief executive officer now directly owns 441,058 shares in the company, valued at $16,433,821.08. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Cytokinetics Stock Performance
Shares of CYTK stock opened at $35.33 on Friday. Cytokinetics, Incorporated has a 12 month low of $33.60 and a 12 month high of $55.80. The company has a debt-to-equity ratio of 1.77, a quick ratio of 9.40 and a current ratio of 9.40. The company’s fifty day moving average price is $41.96 and its 200-day moving average price is $44.15.
Cytokinetics (NASDAQ:CYTK – Get Rating) last announced its quarterly earnings results on Wednesday, March 1st. The biopharmaceutical company reported ($1.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.23). The firm had revenue of $1.96 million during the quarter, compared to the consensus estimate of $7.10 million. Cytokinetics had a negative return on equity of 1,401.63% and a negative net margin of 410.89%. The business’s revenue for the quarter was down 96.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.36) EPS. Equities analysts expect that Cytokinetics, Incorporated will post -4.41 earnings per share for the current year.
Wall Street Analyst Weigh In
Hedge Funds Weigh In On Cytokinetics
A number of hedge funds have recently bought and sold shares of CYTK. Vanguard Group Inc. boosted its stake in Cytokinetics by 25.1% in the 1st quarter. Vanguard Group Inc. now owns 8,741,124 shares of the biopharmaceutical company’s stock worth $321,760,000 after purchasing an additional 1,751,405 shares in the last quarter. BlackRock Inc. boosted its stake in Cytokinetics by 8.6% in the 3rd quarter. BlackRock Inc. now owns 14,569,992 shares of the biopharmaceutical company’s stock worth $705,918,000 after purchasing an additional 1,156,696 shares in the last quarter. Norges Bank bought a new position in Cytokinetics in the 4th quarter worth about $38,459,000. American Century Companies Inc. lifted its stake in Cytokinetics by 155.1% during the 4th quarter. American Century Companies Inc. now owns 1,181,817 shares of the biopharmaceutical company’s stock valued at $54,151,000 after acquiring an additional 718,472 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its stake in Cytokinetics by 119.7% during the 3rd quarter. Price T Rowe Associates Inc. MD now owns 1,093,447 shares of the biopharmaceutical company’s stock valued at $52,978,000 after acquiring an additional 595,708 shares during the period.
Cytokinetics Company Profile
Cytokinetics, Inc is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.
- Get a free copy of the StockNews.com research report on Cytokinetics (CYTK)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.